GEN-MKT-18-7897-A
Mar 31, 2025 | Blogs, Pharma | 0 comments
It is no secret that (bio)pharmaceutical research and development is complex, both scientific and regulatory processes. Here is an overview of just some of the ways SCIEX is working to support these challenges.
Integration
Advanced analytical systems, like mass spectrometers and liquid chromatography systems, have a crucial role to play in guiding the pharmaceutical industry’s journey toward digital integration. We prioritize the development of expansive digital platforms that seamlessly merge various systems and data sources and establish robust standards. Embracing innovative technologies such as the internet of things and advanced analytics will allow us to implement real-time monitoring and predictive maintenance, ultimately optimizing operational efficiency for pharmaceutical companies.
Here is an example of An automated, real-time measurement of the kinetic hydrolysis of a glucuronide using the Echo® MS+ system with ZenoTOF 7600 system
Software
Embedding compliance features into our solutions is crucial to ensure alignment with evolving regulatory frameworks. Equally important, is a commitment to providing comprehensive training and continuous support to facilitate the smooth adoption of digital solutions within pharmaceutical companies. This proactive approach will empower our customers to navigate the complexities of digital transformation confidently and competently.
To allow our existing and potential new customers to trail our new software features, we provide a virtual trial of SCIEX OS software.
Register for a test drive SCIEX OS software, here.
Ultimately, we should aim to drive the industry toward achieving operational excellence within the interconnected digital landscape. Through ongoing innovation and strategic partnership, life science technology providers can make a meaningful impact in shaping the future of pharmaceutical operations, ensuring agility, resilience, and efficacy in an increasingly digital world.
Learn more about how SCIEX can help here
As therapeutic pipelines continue to diversify, bioanalysis is being asked to do more than ever before. From small molecules to complex biologics, today’s scientists must generate high‑quality, reliable data across a growing range of molecule types and workflows, often under increasing time pressure.
Regulated laboratories are evolving faster than ever. New analytical modalities, higher sample throughput, increasing regulatory scrutiny, and leaner teams are reshaping how work gets done. At the same time, expectations for data integrity, standardization, and operational efficiency continue to increase complexity and/or scope. In this environment, LC-MS software is no longer simply an instrument control platform—it has become a critical part of a laboratory’s quality management system. The question is no longer whether your lab has changed, but whether your software has evolved to support the way regulated labs operate today, and if they are ready and able to meet the demands, they will face tomorrow.
Analyst software has long been a trusted foundation in regulated LC-MS laboratories—and for many, it still performs reliably today. But regulated environments are evolving faster than ever. As labs transition to Windows 11, strengthen cybersecurity policies, modernize IT infrastructure, and prepare for future compliance expectations, software decisions are no longer just about what works today—they’re about managing tomorrow’s risk. Analyst will not be supported on Windows 11. While some labs may continue operating in unsupported environments temporarily, the bigger question is: when that risk becomes reality, will your lab be reacting under pressure—or executing a planned mitigation strategy with confidence?
Posted by
You must be logged in to post a comment.
Share this post with your network